Israel Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Israel Pharmaceuticals and Healthcare Report

Israel Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Israel Pharmaceuticals and Healthcare Report
Published Oct 01, 2016
114 pages — Published Oct 01, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

Government resistance to aligning domestic patent law with international standards. Israel s parallel import policy threatens foreign company margins. Potential reduction in prices under new pricing system proposals. The country s extremely tense domestic and external situation, both in terms of political instability and the Palestinian-Israeli conflict, threatens long-term market stability. Increasing cooperation on health by Gulf Cooperation Council members may leave Israel more politically and economically isolated than ever. A sharp appreciation of the shekel could cause Israel s exports to become uncompetitive. Discriminatory healthcare coverage disadvantaging those with Palestinian parentage tarnishes Israel s standing in the international community.

...In July ----, Kantar Health, a leading global healthcare consulting and market research firm, announced it would expand its presence in Israel to better partner with companies in the rapidly growing life sciences industry. Kantar Health will offer marketing insights and real-world evidence solutions to the local biotech, medical technology and mHealth companies that populate Israel s hub of healthcare innovation. ...In July ----, Kantar Health, a leading global healthcare consulting and market research firm, announced it would expand its presence in Israel to better partner with companies in the rapidly growing life sciences industry. Kantar Health will offer marketing insights and real-world evidence solutions to the local biotech, medical technology and mHealth companies that populate Israel s hub of healthcare innovation. In August ----, Novartis announced it would support the development of a non-alcoholic steatohepatitis (NASH) drug by its Israeli partner BioLineRx. ...In August ----, Novartis announced it would support the development of a non-alcoholic steatohepatitis (NASH) drug by its Israeli partner BioLineRx. The arrangement sees BioLineRx, which Novartis works with to scout opportunities in Israel, in-license the NASH asset under its R&D framework.

...Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the EU s acceptance of Israel s good manufacturing practice certificates without the need for additional testing. New proactive policies promoting healthier diets and regulations against unhealthy products could reduce the country s disease burden in the medium to long term. ...

  
Source:
Document ID
1748-1961
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Israel Pharmaceuticals and Healthcare Report" Oct 01, 2016. Alacra Store. Dec 07, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Israel-Pharmaceuticals-and-Healthcare-Report-2026-539>
  
APA:
Business Monitor International - Industry Reports. (2016). Israel Pharmaceuticals and Healthcare Report Oct 01, 2016. New York, NY: Alacra Store. Retrieved Dec 07, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Israel-Pharmaceuticals-and-Healthcare-Report-2026-539>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.